Truist Securities Reiterates Hold on Integra Lifesciences, Lowers Price Target to $13
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Truist Securities analyst Ravi Misra reiterates Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.
Truist Securities analyst Ravi Misra reiterates Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.